This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Christopher Lee Mulligan: Innovator in Cancer Treatment
Introduction
Christopher Lee Mulligan is a notable inventor based in Bordentown, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and development efforts. His work focuses on enhancing therapeutic efficacy in immunotherapy.
Latest Patents
Mulligan holds a patent for "Immunotherapeutic dosing regimens comprising pomalidomide and an anti-CS1 antibody for treating cancer." This invention relates to therapeutic dosing regimens and combinations aimed at improving the effectiveness of anti-CS1 antibodies when used alongside one or more immunotherapeutic agents. He has 1 patent to his name.
Career Highlights
Mulligan is currently employed at Bristol-Myers Squibb Company, a leading biopharmaceutical firm known for its commitment to discovering and developing innovative medicines. His role at the company allows him to contribute to groundbreaking research in cancer therapies.
Collaborations
Mulligan has worked alongside talented colleagues, including Justin Blake Bartlett and Michael Darron Robbins. Their collaborative efforts have further advanced the research and development of effective cancer treatments.
Conclusion
Christopher Lee Mulligan's contributions to cancer treatment through his innovative patent and work at Bristol-Myers Squibb Company highlight his dedication to improving patient outcomes. His research continues to pave the way for advancements in immunotherapy.